Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.373
-0.018 (-4.65%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Femasys Revenue
In the year 2025, Femasys had annual revenue of $2.29M with 40.77% growth. Femasys had revenue of $813.39K in the quarter ending December 31, 2025, with 39.86% growth.
Revenue (ttm)
$2.29M
Revenue Growth
+40.77%
P/S Ratio
9.82
Revenue / Employee
$42,469
Employees
54
Market Cap
22.53M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 86.55M |
| Retractable Technologies | 38.27M |
| Bionano Genomics | 28.51M |
| Precision Optics Corporation | 24.42M |
| Jin Medical International | 20.69M |
| Nephros | 18.79M |
| Ekso Bionics Holdings | 12.80M |
| Milestone Scientific | 8.97M |
FEMY News
- 4 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - GlobeNewsWire
- 3 months ago - Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - GlobeNewsWire
- 4 months ago - Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - GlobeNewsWire
- 5 months ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 6 months ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 6 months ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire